aTyr Pharma Inc.

227 articles with aTyr Pharma Inc.

• aTyr Pharma Announces First Quarter 2017 Operating Results

  5/12/2017

• aTyr Pharma Presents Analyses Of Resolaris Phase Ib/II Trial In Patients With Limb Girdle Muscular Dystrophy 2B And Facioscapulohumeral Muscular Dystrophy At The American Academy of Neurology 69th Annual Meeting

  4/24/2017

• aTyr Pharma Presents Analyses Of Resolaris Phase Ib/II Trial In Patients With Limb Girdle Muscular Dystrophy 2B And Facioscapulohumeral Muscular Dystrophy At American Academy of Neurology 69th Annual Meeting

  4/24/2017

• aTyr Pharma Announces Promising Top-Line Results From Resolaris Phase Ib/II Clinical Trial In Patients With Early Onset Facioscapulohumeral Muscular Dystrophy

  4/24/2017

• aTyr Pharma Announces Promising Top-Line Results From Resolaris Phase Ib/II Clinical Trial in Patients With Early Onset Facioscapulohumeral Muscular Dystrophy

  4/24/2017

• aTyr Pharma Announces Appointment Of Timothy P. Coughlin To Its Board Of Directors

  4/11/2017

• aTyr Pharma Announces Appointment Of Timothy P. Coughlin To Its Board Of Directors

  4/11/2017

• aTyr Pharma Announces Appointment Of Jeffery S. Hatfield To Its Board Of Directors

  4/3/2017

• aTyr Pharma Announces Fourth Quarter And Year-End 2016 Operating Results

  3/17/2017

• aTyr Pharma Announces Issuance Of U.S. Patent That Extends Patent Protection Of Physiocrines Derived From 20 Out Of 20 Human tRNA Synthetases

  3/15/2017

• aTyr Pharma Receives EMA Orphan Drug Designation For The Treatment Of Limb Girdle Muscular Dystrophy With Resolaris

  3/3/2017

• aTyr Pharma Receives U.S. FDA Orphan Drug Designation For The Treatment Of Limb Girdle Muscular Dystrophy With Resolaris

  2/28/2017

• aTyr Pharma Release: FDA Grants Fast Track Designation For Company's Resolaris To Treat Limb Girdle Muscular Dystrophy 2B And Removes Partial Clinical Hold For Resolaris

  1/18/2017

• aTyr Pharma Reports Promising Signals Of Clinical Activity In Multiple Rare Genetically Distinct Myopathies With Resolaris In Exploratory Trials

  12/13/2016

• aTyr Pharma Enters Into $20 Million Credit Facility

  11/21/2016

• aTyr Pharma Announces Third Quarter 2016 Operating Results

  11/14/2016

• aTyr Pharma Receives FDA Fast Track Designation For Resolaris To Treat Facioscapulohumeral Muscular Dystrophy (FSHD)

  10/24/2016

• aTyr Pharma Presents Additional Data For Resolaris Phase 1b/2 Trial In Adult Patients With Facioscapulohumeral Muscular Dystrophy At The 21st International Annual Congress Of The World Muscle Society

  10/6/2016

• aTyr Pharma Announces Presentation At The 21st International Annual Congress Of The World Muscle Society

  9/29/2016

• aTyr Pharma Appoints Industry Veteran In Novel Biology Biologics, David J. King, Phd, As Senior Vice President, Research

  9/22/2016